leadf
logo-loader
RNS
viewHemoGenyx Pharmaceuticals

Hemogenyx Pharma Plc - Grant of Options

RNS Number : 8331W
Hemogenyx Pharmaceuticals PLC
21 August 2020
 

21 August 2020

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Grant of Options

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 5,000,000 ordinary shares of 1p each in the capital of the Company ("Share Options") to the Company's co-founder and CEO Dr Vladislav Sandler.

 

The details of the Share Options granted are set out below:

Name

Position

Number of Share Options Granted

Exercise Price (pence)

Vesting Date

Expiry Date

Dr Vladislav Sandler

CEO

5,000,000

7

Immediate

19 August 2025

 

Following the grant of the Share Options there are, in aggregate, 42,465,786 ordinary shares of 1p each in the Company under option held by directors, employees and members of the Scientific Advisory Board of the Company, representing 9.79% of the issued ordinary share capital of the Company.

 

Enquiries:

 

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Peter Redmond, Director

[email protected]





SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev







Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow



 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):

1.

Details of PDMR/person closely associated with them

a)

Name

Dr Vladislav Sandler

b)

Position/status

CEO, Executive Director

c)

Initial notification/
amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.07

5,000,000

 

 

d)

Aggregated information

-     Aggregated volume

-     Price

Price(s)

Volume(s)

N/A - variable

5,000,000

e)

Date of the transaction

20/08/2020

f)

Place of the transaction

Outside of a trading venue

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHDZGZRRMRGGZG

Quick facts: HemoGenyx Pharmaceuticals

Price: 9.2

Market: LSE
Market Cap: £39.89 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

4 min read